What’s The Latest Depo Provera Lawsuit Update?
The Depo-Provera multidistrict litigation (MDL) has entered a key phase, with plaintiffs’ lawyers reviewing over 10 million documents that Pfizer presented. The court recently aligned key deadlines for discovery and motion filings. Judge Rodgers also confirmed that pilot case trials will begin in late 2026 or early 2027 to guide potential future settlements.
If you’re facing health issues after taking Depo-Provera injections, your case may qualify for MDL. However, its success depends on timely, documented action. At Uptown Injury Law, PLLC, our attorneys will handle every legal step of your claim. We file a Depo-Provera lawsuit, prepare discovery responses, and gather key evidence to strengthen your position. Call 917-540-8728 now to speak with a top-rated Depo-Provera lawyer.
What Are The New Developments in the Depo-Provera Lawsuit?
In June 2025, the court issued Case Management Order No. 3 confirming discovery deadlines. The court set July 25 as the deadline to complete preemption discovery, with summary judgment briefs due on August 22. Meanwhile, general causation discovery will continue into 2026, focusing on expert testimony and Pfizer’s internal documents. Here’s a complete timeline of the latest developments in the lawsuit of injectable contraceptive Depo-Provera:
June 19, 2025: Court Sets Updated Timeline for Key Phases of the Lawsuit
The court has approved new deadlines that require both Pfizer and plaintiffs to complete discovery related to Pfizer’s preemption defense by July 25. After that, formal requests to resolve the case without a trial must be filed by August 22. On the other hand, the discovery of general causation will go on till early 2026. This includes expert depositions, where medical experts are questioned under oath about their opinions. These interviews must be finished by January 10. Any legal challenges to their testimony are then due by February 10.
June 17, 2025: Plaintiffs Continue Discovery Review
Ahead of the upcoming court conference, both plaintiffs and defendants filed a joint status update outlining ongoing case developments. At this stage, plaintiffs’ attorneys will continue reviewing millions of documents already produced by the defendants.
June 10, 2025: Judge Schedules Key Hearing on Pfizer’s Preemption Defense
Judge Rodgers will hear arguments on September 29 regarding Pfizer’s attempt to dismiss the lawsuits. Pfizer argues it can’t be sued under state law because the FDA rejected a proposed warning about brain tumor risks. Plaintiffs respond that Pfizer still had a legal duty to act on emerging safety data. However, the outcome will come in October, and it’ll decide whether the MDL will move forward.
June 8, 2025: Depo-Provera Lawsuits Proceed in Multiple State Courts
In addition to the federal MDL, Depo-Provera lawsuits are now moving forward in state courts across the U.S. California currently has six active cases, with coordination efforts initiated by the Judicial Council. New York has the largest number, with 60 pending cases and formal consolidation expected. Other states with ongoing litigation include Pennsylvania, Illinois, New Mexico, and Delaware.
June 2, 2025: Court Approves Process to Fix Plaintiff Complaints
Judge Rodgers approved a streamlined method for correcting errors in plaintiff filings. The new protocol requires each claimant to confirm the specific Depo-Provera product they used and identify the type of diagnosed brain tumor.
May 20, 2025: Judge Defines Evidence Standards
In Pretrial Order 22, Judge Rodgers outlined what each plaintiff must submit to remain in the MDL. This includes a Proof of Use/Injury Questionnaire and documented medical proof of Depo-Provera usage and tumor diagnosis.
May 13, 2025: Defendants Produce One Million Documents
Pfizer and its co-defendants produced 1 million documents, with 8 million pages, as part of pretrial discovery. Plaintiffs’ attorneys are now examining this material for data that reveals what the companies knew about the risk of brain tumors.
May 1, 2025: Generic Manufacturers Ordered Into Discovery
Judge Rodgers directed the Co-defendant companies (Greenstone and Viatris) to fully participate in pretrial discovery. However, Prasco, another co-defendant, may be excluded due to a prior agreement. This order ensures that women who took generic forms of Depo-Provera will also have their claims properly investigated.
April 16, 2025: Generic Defendants Miss Filing Deadline
Greenstone and Viatris failed to meet a key deadline for court-ordered affidavits. They eventually submitted the required documents, but Judge Rodgers warned that she would not tolerate further delays.
April 1, 2025: Record Collection Made Easier for Plaintiffs
A new order from Judge Rodgers eased access to medical and pharmacy records, which are essential to building each plaintiff’s case. This step removes barriers for women who used Depo-Provera years ago and now struggle to retrieve older documentation.
March 18, 2025: Plaintiffs Permitted to File Directly in Florida
The court authorized direct filing in the Northern District of Florida, allowing plaintiffs to avoid their home state courts. This speeds up the filing process and keeps all cases under consistent judicial supervision.
March 3, 2025: Court Appoints Special Master and Data Administrator
Judge Rodgers appointed Judge David Herndon as Special Master to assist with case management. She also appointed a data administrator to oversee the millions of pages of discovery documents, including internal Pfizer records, medical evidence, and expert materials submitted by both sides.
February 26, 2025: Legal Teams Discuss Next Phase of Litigation
Attorneys for both plaintiffs and defendants met with court officials to outline the next steps in the MDL. Topics included leadership appointments, discovery timelines, and eligibility for generic Depo-Provera users.
February 21, 2025: Lawsuits Begin Transferring Into MDL 3140
Federal courts have started moving state-level cases into the newly formed Depo-Provera MDL. Judge Rodgers held a case management conference to organize the proceedings and set early priorities.
February 7, 2025: Depo-Provera MDL 3140 Officially Established
The Judicial Panel on Multidistrict Litigation (JPML) approved the consolidation of Depo-Provera brain tumor lawsuits into MDL 3140. All cases will proceed under Judge M. Casey Rodgers in the Northern District of Florida.
February 3, 2025: Venue Debate Delays MDL Finalization
At a key hearing, plaintiffs asked for the MDL to be based in California, considering favorable liability laws. However, Pfizer argued for New York. The final decision is due from the panel.
January 16, 2025: Class Action Ruled Out
Attorneys clarified that the litigation will proceed as a multidistrict lawsuit, not a class action. Each woman will keep her individual claim while benefiting from shared discovery and court coordination.
January 2, 2025: MDL Would Expand Legal Options
Plaintiffs’ attorneys explained that the proposed MDL would apply not only to existing cases but also to future claims. This would help women who develop brain tumors later file lawsuits without starting from scratch.
December 2, 2024: Six Drug Companies Named as Defendants
The MDL petition lists Pfizer, Pharmacia, Greenstone, Viatris, and Prasco as defendants. These companies manufactured or distributed the injectable birth control that is now under legal scrutiny.
November 27, 2024: Official MDL Request Filed
Attorneys filed a formal motion asking the JPML to consolidate 22 Depo-Provera lawsuits. They proposed the Northern District of California as the venue for central proceedings.
November 22, 2024: Medical Groups Added as Defendants
A new lawsuit filed in California names not only drug manufacturing companies, but also health providers and insurers. The suit claims they had access to independent research but still promoted the injection without warning patients of its dangers.
November 14, 2024: Lawsuit Inquiries Continue to Rise
Law firms report growing concern among women who used Depo-Provera and now suffer from neurological symptoms. Many are undergoing testing for brain tumors, specifically meningiomas, and exploring whether they have grounds to file a lawsuit.
How Does MDL Streamline Depo-Provera Lawsuit Cases?
MDL streamlines Depo-Provera cases by combining similar lawsuits into one federal court for pretrial proceedings, such as discovery, motions, and expert testimony. This ce111ntralization speeds up the discovery process, reduces legal costs, and ensures consistent rulings. Although grouped for efficiency, each plaintiff has an individual claim. This means they may still receive a separate Depo-Provera lawsuit settlement or trial outcome.
The currently active Depo-Provera MDL No. 3140 was established in 2025 in the Northern District of Florida. It consolidates over 400 lawsuits that claim prolonged Depo-Provera use caused intracranial meningioma and other serious side effects. The MDL framework allows attorneys to coordinate strategy, exchange findings, and present collective arguments against Pfizer’s defense. This joint approach increases pressure on the manufacturing company and improves the chances of securing fair compensation for each case.
What is the Purpose of Pilot Cases in Depo-Provera Litigation?
Pilot cases, also known as bellwether trials, serve as test runs for the broader Depo-Provera multidistrict litigation. The judge carefully selects these cases to represent common issues found across the larger group of plaintiffs. They allow both sides to see how juries respond to the evidence, expert testimony, and legal arguments.
While the outcomes of bellwether trials do not directly affect other cases, they help set the tone for future negotiations. If juries rule in favor of plaintiffs, it often pressures the defendant to consider settlement options more seriously. However, if the verdict seems against the plaintiffs, their lawyers have to revise their legal strategy or prepare for extended litigation.
According to the Northern District Court, Judge Casey Rodgers has selected five pilot cases to move forward with early discovery and trial preparation in MDL No. 3140. Although these cases are not official bellwether trials, they serve a similar purpose. According to the court, they will help narrow the key disputes across the MDL, such as general causation or preemption. These cases also offer both sides a chance to review strengths and weaknesses early in the process. As the litigation progresses, the judge may finalize additional pilot cases based on case needs.
How Did the Court Simplify Record Collection for Depo-Provera Lawsuits?
Judge Rodgers simplified record collection by approving standardized HIPAA/HITECH authorization forms. She also allowed plaintiffs to request Pfizer’s distribution data directly. These changes help lawyers access pharmacy, insurance, and medical records more quickly. As a result, even those with older cases can now prove Depo-Provera use more easily.
This process matters because many Depo-Provera shot users received injections years or even decades ago. Over time, records from doctors, clinics, or pharmacies may have been lost. The court’s order helps close these gaps by asking Pfizer to share distribution data. This may confirm where and when Depo-Provera was administered. For women who received injections through public health programs or closed clinics, this system makes it possible to still access key records.
In addition, these streamlined procedures reduce delays during discovery. Depo-Provera patients no longer need to chase down multiple providers for documents one by one. Instead, their legal teams can submit one form to multiple sources at once, saving time and improving case accuracy.
What Are the Requirements for the Injury Proof Questionnaire in the Depo-Provera MDL?
According to the Pretrial Order No. 17, the Injury Proof Questionnaire requires plaintiffs to confirm the use of Depo-Provera and the meningioma diagnosis with medical, pharmacy, or insurance records. They must upload these documents through MDL Centrality. The documents should include the plaintiff’s name, match the claimed timeline, and be verified under penalty of perjury. Here are the additional requirements for each form:
| Proof of Use | Proof of Injury |
|---|---|
| Proof of a doctor prescribing or administering the contraceptive injection | Confirmed diagnosis of a meningioma subtype (e.g., skull base meningioma) |
| Date of the action (e.g., when the birth control injection was prescribed) | Diagnosis date (must be within one year of the date in the questionnaire) |
| Maximum of 5 pages per product | Maximum of 5 pages per diagnosis |
| Documents: Prescription records, pharmacy logs, insurance records, and statements from a doctor or clinic | Documents: Diagnostic medical records, insurance data, and the written confirmation of diagnosis from a neurologist |
If any submission lacks the required details, the court will notify and give plaintiffs 10 business days to fix them. Failing to address these issues may prompt the judge to issue a show cause order and potentially dismiss the case.
Is There Any Time Limit to Submit the Injury Questionnaire?
Yes, the court has set a strict statute of limitations for submitting the Injury Proof Questionnaire in MDL 3140. If your case was already part of the MDL as of March 14, 2025, you must submit it by July 14, 2025. For newer cases, the deadline is 120 days from the date your case joins the litigation, as per About Lawsuits.
However, the court may allow extensions in rare situations. This applies when medical records are hard to retrieve despite constant efforts. Still, timely submission remains important. It can strengthen your position in the lawsuit. Those who file early with complete documentation may be considered for pilot cases or early settlements. In contrast, late or incomplete submissions can reduce negotiating leverage, delay progress, or result in exclusion from important litigation phases.
If you need help meeting your Depo-Provera lawsuit deadline, contact Uptown Injury Law, PLLC. Our legal team will guide you through the documentation process. We ensure all your documents are submitted on time and in full compliance with MDL requirements. Call 917-540-8728 to connect with our expert attorneys for a free consultation.
How Are Generic Depo-Provera Manufacturers Involved in Recent Lawsuit Updates?
Generic Depo-Provera manufacturers, including Greenstone, Viatris, and Prasco, were named in the MDL for failing to warn users about tumor risks. The court initially required them to join the discovery and submit related records. Their involvement focused on whether they distributed or labeled the product without providing proper safety warnings.
However, on June 11, 2025, Judge Rodgers issued a new case order. It indicates that the court will likely remove these generic manufacturers from the lawsuit. At a May 30 hearing, plaintiffs’ lawyers explained that Greenstone, Viatris, and Prasco had minimal involvement. Therefore, both sides now expect the court to dismiss them after a final review.
How Did Pfizer’s 1 Million Document Turnover Impact the Depo Shot Lawsuit?
Pfizer’s release of 1 million documents, with 8 million pages, gave plaintiffs key evidence to challenge the company’s liability in the Depo-Provera lawsuits. The documents include internal communications, research data, and regulatory filings, offering insight into Pfizer’s knowledge of tumor risks. They will help lawyers address key issues such as general causation and preemption. Here is how the large document volume can impact new Depo-Provera lawsuits:
- Pfizer may claim FDA approval shields it from state law claims. But if documents reveal the company hid safety risks, that defense weakens, and plaintiffs can seek full compensation.
- To advance their case, plaintiffs must show that long-term Depo-Provera use can cause meningioma tumors. Internal studies, adverse event logs, and company emails may support this link and strengthen expert testimony on general causation.
- Plaintiffs’ lawyers are reviewing the documents for patterns, gaps, and evidence that Pfizer knew about Depo-Provera’s link to brain tumors. These findings will shape their legal strategy and strengthen preparation for trial or settlement.
Stay Updated on Your Depo-Provera Lawsuit — Get a Free Case Review From Uptown Injury Law, PLLC, Today!
If you’ve developed a brain tumor after taking multiple Depo-Provera birth control shots, you’re not alone. Many women are now discovering links between their long-term health issues and this drug. However, the process of suing the manufacturing company is complex. You’d require strong legal support to secure fair compensation.
At Uptown Injury Law, PLLC, our attorneys track every Depo-Provera MDL update, so you don’t miss a step. We handle the filing, review Pfizer’s internal records, and submit evidence linking Depo-Provera usage to your condition. You won’t have to manage court deadlines alone. Call 917-540-8728 now and let us protect your legal rights.
FAQs
What Specific Health Issues Are Linked to Depo-Provera?
Drug Depo-Provera can cause meningioma tumors in both the brain and spinal cord, especially with long-term use. This leads to symptoms such as vision loss, severe headaches, and mobility issues. Some users also report hormonal side effects, such as bone thinning, uterine fibroids, or thickening cervical mucus after prolonged Depo-Provera intake. It has medroxyprogesterone acetate, which is linked to these diseases.
How Long Does It Take to Resolve a Depo-Provera Lawsuit?
Depo-SubQ Provera lawsuits usually take several months to a few years to resolve. However, MDL coordination can speed up early steps such as record collection, expert sharing, and legal motions. Usually, Depo-Provera users with strong documentation and clear medical links settle earlier. But if key records are missing or Pfizer disputes liability, the process can take longer.
Are Settlements Common in Depo-Provera Lawsuits?
Yes, many pharmaceutical lawsuits end in settlement, including Depo Provera cases. In MDL, attorneys use pilot cases to test legal arguments and assess jury reactions. These early outcomes help shape broader negotiations. If plaintiffs win, Pfizer may feel pressure to settle. However, each case remains individual. Depo-Provera settlement amounts vary depending on injury severity, strength of medical records, and documented Depo-Provera use.
Is Pfizer the Only Defendant in the Depo-Provera Lawsuits?
Yes, Pfizer remains the main defendant in the Depo-Provera meningioma lawsuit because it manufactures and markets the drug. The MDL focuses on how Pfizer failed to warn users about brain tumor risks. The plaintiffs also named three generic manufacturers, Greenstone, Viatris, and Prasco, for distributing similar products without proper warnings. However, after reviewing their roles, the court announced these companies played a limited part and may soon exit the case.
How Is Liability Determined in the Depo-Provera Class Action Lawsuit?
Liability in Depo-Provera brain tumor lawsuits depends on proving that Pfizer knew about Depo-Provera’s risks. Plaintiffs also need to prove the company failed to warn doctors or users. In addition, they must show a clear connection between the drug and their injury. Expert testimony, internal documents, and medical records help establish a strong claim in such cases.
How Are Damages Calculated in Depo-Provera Birth Control Claims?
In a Depo-Provera lawsuit, damages refer to the physical, emotional, and financial losses caused by the drug. These primarily include medical costs for treating meningiomas and lost income. If future treatment or long-term care is expected, those expenses are included as well. Courts calculate the total value by reviewing medical records, employment history, expert opinions, and how the injury links to Depo-Provera use.
Can a Meningioma Brain Tumor Appear Years After Using Depo-Provera?
Yes, meningiomas can develop years after you receive Depo-Provera injections. Doctors believe the hormone progestin, found in Depo-Provera, may trigger tumor growth. However, these tumors often grow slowly and may go unnoticed for a long time. Courts allow older Depo-Provera claims if medical records, imaging reports, and prescription history clearly show Depo-Provera use before diagnosis. In such cases, MRI scans and doctor statements may also help confirm the diagnosis timeline and establish a link.
